Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
D. Azria(Inserm), J.P. Gérard(Centre Antoine Lacassagne), Y. Bécouarn, Thierry Conroy(Inserm), Marta Jarlier(Institut de Recherche en Cancérologie de Montpellier), Christophe Hennequin(Inserm), Olivier Dupuis(Clinique Victor Hugo), Jean-François Berdah(American Society of Clinical Oncology), Laurent Bedenne(CHU Dijon Bourgogne), V. Vendrely(Centre Hospitalier Universitaire de Bordeaux), J. Doyen(Centre Antoine Lacassagne), Éric François(Centre Antoine Lacassagne), Isabelle Martel‐Lafay(Centre Léon Bérard), Pierre-Luc Etienne, Laurent Mineur(Institut Sainte Catherine), Olivier Bouché(CHU Dijon Bourgogne), Béata Juzyna(UniCancer Group), Bernard Denis(American Society of Clinical Oncology), Jean‐François Seitz(Aix-Marseille Université), Marc-André Mahé(American Society of Clinical Oncology), Gérard Lledo(American Society of Clinical Oncology), S. Gourgou-Bourgade(CEA Valduc), G. Roche(Institute Cancer De La Loire Lucien Neuwirth), X. Mirabel(American Society of Clinical Oncology)
Cited by 106
Related Papers
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
|New England Journal of Medicine|2006|2.7k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k